Trifecta Capital Advisors’s Idexx Laboratories IDXX Stock Holding History

Trifecta Capital Advisors’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.58K	Sell	3 -157	-98%	-$88.1K	﹤0.01%	321
2026 Q1	$89.9K	Sell	160 -140	-47%	-$89.8K	0.01%	153
2025 Q4	$203K	Sell	300 -105	-26%	-$71.5K	0.03%	104
2025 Q3	$259K	Hold	405	–	–	0.04%	91
2025 Q2	$217K	Sell	405 -200	-33%	-$95.6K	0.04%	96
2025 Q1	$254K	Hold	605	–	–	0.05%	71
2024 Q4	$250K	Hold	605	–	–	0.05%	75
2024 Q3	$306K	Sell	605 -60	-9%	-$29.1K	0.06%	70
2024 Q2	$324K	Buy	665 +660	+13,200%	+$331K	0.07%	69
2024 Q1	$2.7K	Hold	5	–	–	﹤0.01%	273
2023 Q4	$2.78K	Hold	5	–	–	﹤0.01%	294
2023 Q3	$2.19K	Hold	5	–	–	﹤0.01%	298
2023 Q2	$2.51K	Hold	5	–	–	﹤0.01%	279
2023 Q1	$2.5K	Hold	5	–	–	﹤0.01%	284
2022 Q4	$2.04K	Buy	+5	New	+$1.94K	﹤0.01%	298

Other funds holding IDXX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Trifecta Capital Advisors's IDXX Position: Q2 2026 in Review

Trifecta Capital Advisors reduced its Idexx Laboratories (IDXX) stake by 98% in Q2 2026, selling an estimated $88.1K and leaving 3 shares worth $1.58K. The position accounts for ﹤0.01% of the portfolio, ranked #321.

Trifecta Capital Advisors first reported a position in IDXX in Q4 2022 and has held it in 15 quarters since. The position peaked at $324K in Q2 2024. 1,305 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

Trifecta Capital Advisors held 3 shares of Idexx Laboratories worth $1.58K as of Q2 2026.
Trifecta Capital Advisors sold 157 Idexx Laboratories shares in Q2 2026, an estimated $88.1K.
Idexx Laboratories made up ﹤0.01% of Trifecta Capital Advisors's portfolio in Q2 2026, its #321 holding.
Trifecta Capital Advisors first reported a position in Idexx Laboratories in Q4 2022 and has held it in 15 quarters since.
Trifecta Capital Advisors's Idexx Laboratories position peaked at $324K in Q2 2024.
1,305 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Trifecta Capital Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.